CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity

CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity

Background Despite recent advances in immunotherapy, many patients with non-small cell lung cancer (NSCLC) do not respond to immune checkpoint inhibitors (ICI). Resistance to ICI may be driven by suboptimal priming of antitumor T lymphocytes due to poor antigen presentation as well as their exclusio...

Full description

Bibliographic Details
Main Authors: Bin Liu, Rui Li, Edward B Garon, Steven M Dubinett, Kostyantyn Krysan, Tianhao Zhang, Aaron E Lisberg, Ramin Salehi-Rad, Raymond J Lim, Yushen Du, Linh M Tran, Stephanie L Ong, Zi Ling Huang, Camelia Dumitras, Stacy J Park, William Crosson, Bitta Kahangi, Jensen Abascal, Christopher Seet, Michael Oh, Maryam Shabihkhani, Manash Paul
Format: Article
Language:English
Published: BMJ Publishing Group 2023-09-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/9/e006896.full

Similar Items

Similar Items